Azithromycin versus Doxycycline for UrogenitalChlamydia trachomatisInfection | Zendy

William M. Geisler | Zendy; Apurva Uniyal | Zendy; Jeannette Y. Lee | Zendy; Shelly Lensing | Zendy; Shacondra M. Johnson | Zendy; Raymond Perry | Zendy; Carmel M. Kadrnka | Zendy; Peter R. Kerndt | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Azithromycin versus Doxycycline for UrogenitalChlamydia trachomatisInfection

Author(s) -

William M. Geisler,

Apurva Uniyal,

Jeannette Y. Lee,

Shelly Lensing,

Shacondra M. Johnson,

Raymond Perry,

Carmel M. Kadrnka,

Peter R. Kerndt

Publication year - 2015

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1502599

Subject(s) - azithromycin , medicine , chlamydia trachomatis , doxycycline , chlamydia , population , clinical endpoint , randomized controlled trial , confidence interval , sexually transmitted disease , genitourinary system , gynecology , immunology , antibiotics , biology , microbiology and biotechnology , environmental health , syphilis , human immunodeficiency virus (hiv)

Urogenital Chlamydia trachomatis infection remains prevalent and causes substantial reproductive morbidity. Recent studies have raised concern about the efficacy of azithromycin for the treatment of chlamydia infection.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research